Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 9/2011

01-09-2011 | Review

TRAIL and guardian angel of genome integrity: ATM boards TRAIL blazer

Authors: Ammad Ahmad Farooqi, Salman Waseem, Muhammad Sajjad Ashraf, Muhammed Javed Iqbal, Shahzad Bhatti

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2011

Login to get access

Abstract

Prostate cancer is a multifaceted progressive multistep disorder that arises because of accumulation of genetic and epigenetic abnormalities, which escort to the transformation of normal cells into malignant derivatives. Despite tremendous strides have been made in the understanding of prostate cancer biology, yet approaches towards cancer-targeted therapy still face confrontations in standardization. This review brings to attention, the regulators in complex genetic backgrounds to enlighten our understanding of transformation and metastasis in human systems. Recent evidence gives a clue that prostate cancer may be linked to deregulated DNA damage repair processes, as various combinations of targeted deletions in genes controlling cell-cycle checkpoints; apoptosis and DNA repair result in prostate cancer progression and aggressiveness. An insight of the orchestration between DNA damage-based molecular responses and TRAIL provides an understanding of the mechanisms that cause apoptosis and may provide rationale for the development of novel therapeutic strategies.
Literature
go back to reference Farooqi AA, Fayyaz S, Bhatti S, Ismail M, Mansoor Q (2011a) Towards TRAIL to silencing of SMURF and NEDD4: FLIP is flopped. J Exp Integr Med 1:111–116CrossRef Farooqi AA, Fayyaz S, Bhatti S, Ismail M, Mansoor Q (2011a) Towards TRAIL to silencing of SMURF and NEDD4: FLIP is flopped. J Exp Integr Med 1:111–116CrossRef
go back to reference Farooqi AA, Mansoor Q, Rana A, Mashhadi TM, Imran M, Naqi SA, Bhatti S (2011b) SMURF and NEDD4 interference offers therapeutic potential in chaperoning genome integrity. J Exp Integr Med 1:43–50CrossRef Farooqi AA, Mansoor Q, Rana A, Mashhadi TM, Imran M, Naqi SA, Bhatti S (2011b) SMURF and NEDD4 interference offers therapeutic potential in chaperoning genome integrity. J Exp Integr Med 1:43–50CrossRef
go back to reference Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876–885PubMedCrossRef Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876–885PubMedCrossRef
go back to reference Ivanov VN, Zhou H, Partridge MA, Hei TK (2009) Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Cancer Res 69:3510–3519PubMedCrossRef Ivanov VN, Zhou H, Partridge MA, Hei TK (2009) Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Cancer Res 69:3510–3519PubMedCrossRef
go back to reference Johnson GE, Ivanov VN, Hei TK (2008) Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis 13:790–802PubMedCrossRef Johnson GE, Ivanov VN, Hei TK (2008) Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis 13:790–802PubMedCrossRef
go back to reference Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8:782–798PubMedCrossRef Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8:782–798PubMedCrossRef
go back to reference Kim MJ, Kim HB, Bae JH, Lee JW, Park SJ, Kim DW, Park SI, Kang CD, Kim SH (2009) Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway. Biochem Pharmacol 78:573–582PubMedCrossRef Kim MJ, Kim HB, Bae JH, Lee JW, Park SJ, Kim DW, Park SI, Kang CD, Kim SH (2009) Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway. Biochem Pharmacol 78:573–582PubMedCrossRef
go back to reference Kim HB, Kim MJ, Kim DY, Lee JW, Bae JH, Kim DW, Kang CD, Kim SH (2011) High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4, 5-dimethoxy-2-nitrobenzaldehyde. Mol Cancer 10:46PubMedCrossRef Kim HB, Kim MJ, Kim DY, Lee JW, Bae JH, Kim DW, Kang CD, Kim SH (2011) High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4, 5-dimethoxy-2-nitrobenzaldehyde. Mol Cancer 10:46PubMedCrossRef
go back to reference Solier S, Pommier Y (2009) The apoptotic ring: a novel entity with phosphorylated histones H2AX and H2B and activated DNA damage response kinases. Cell Cycle 8:1853–1859PubMedCrossRef Solier S, Pommier Y (2009) The apoptotic ring: a novel entity with phosphorylated histones H2AX and H2B and activated DNA damage response kinases. Cell Cycle 8:1853–1859PubMedCrossRef
go back to reference Solier S, Sordet O, Kohn KW, Pommier Y (2009) Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol Cell Biol 29:68–82PubMedCrossRef Solier S, Sordet O, Kohn KW, Pommier Y (2009) Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol Cell Biol 29:68–82PubMedCrossRef
go back to reference Stagni V, di Bari MG, Cursi S, Condò I, Cencioni MT, Testi R, Lerenthal Y, Cundari E, Barilà D (2008) ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells. Blood 111:829–837PubMedCrossRef Stagni V, di Bari MG, Cursi S, Condò I, Cencioni MT, Testi R, Lerenthal Y, Cundari E, Barilà D (2008) ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells. Blood 111:829–837PubMedCrossRef
go back to reference Stagni V, Mingardi M, Santini S, Giaccari D, Barilà D (2010) ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis. Carcinogenesis 31:1956–1963PubMedCrossRef Stagni V, Mingardi M, Santini S, Giaccari D, Barilà D (2010) ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis. Carcinogenesis 31:1956–1963PubMedCrossRef
go back to reference Stankovic T, Stewart GS, Fegan C, Biggs P, Last J, Byrd PJ, Keenan RD, Moss PA, Taylor AM (2002) Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 99:300–309PubMedCrossRef Stankovic T, Stewart GS, Fegan C, Biggs P, Last J, Byrd PJ, Keenan RD, Moss PA, Taylor AM (2002) Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 99:300–309PubMedCrossRef
go back to reference Wu GS, Burns TF, McDonald ER III, Meng RD, Kao G, Muschel R, Yen T, el-Deiry WS (1999) Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene 18:6411–6418PubMedCrossRef Wu GS, Burns TF, McDonald ER III, Meng RD, Kao G, Muschel R, Yen T, el-Deiry WS (1999) Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene 18:6411–6418PubMedCrossRef
Metadata
Title
TRAIL and guardian angel of genome integrity: ATM boards TRAIL blazer
Authors
Ammad Ahmad Farooqi
Salman Waseem
Muhammad Sajjad Ashraf
Muhammed Javed Iqbal
Shahzad Bhatti
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 9/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-011-0996-y

Other articles of this Issue 9/2011

Journal of Cancer Research and Clinical Oncology 9/2011 Go to the issue